That's an excellent question but quite a detailed one. That information is publicly available on COVAX's website. I would be happy to make sure there is follow-up for that.
At a general level, I can say that COVAX is only in position to procure vaccines that are received through the World Health Organization's emergency use listing. They strive to have a balanced portfolio that reflects the needs of its members. As you would understand, going forward that will include a large percentage of mRNA vaccines, such as Pfizer and Moderna—both vaccines within the COVAX portfolio. They are also planning to deliver significant volumes of Novavax and Johnson & Johnson as other prominent vaccines. Initially, AstraZeneca was a prominent vaccine distributed through the COVAX facility, but there has been a reduced demand for that viral vector vaccine from partner countries, and so it will feature less prominently going forward.